Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Kasper Lamberth, Ph.D., has very recently transitioned to the role as Department Head for Immunogenicity Prediction and Tolerance at Biopharmaceutical Research Unit, Novo Nordisk A/S. Dr. Lamberth joined Novo Nordisk 5 years ago and during this time he has worked with development of immunogenicity prediction tools as well as high throughput screening technologies. Prior to Novo Nordisk A/S, Dr. Lamberth worked for eight years with predictive immunogenicity tools, especially with MHC polymorphism and the identification of T-cell epitopes within the field of infectious diseases at Copenhagen University. Dr. Lamberth holds a MS in Biochemistry and a PhD in Immunology, both from Copenhagen University.
Chemical Biology of Molecules,Class II MHC molecule